Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 30 mg/ml - injection, solution - excipient ingredients: ethanol; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ketorolac trometamol, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose - toradol is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that ketorolac parenteral be used in the immediate post-operative period. patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the dosage and administration section (refer to conversion from parenteral to oral therapy). the total period of treatment utilising the oral and /or intramuscular route of administration is not to exceed five days. general: toradol is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation. there is no satisfactory evidence for the use of toradol in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis)

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; disodium edetate; benzalkonium chloride; octoxinol 40; sodium hydroxide; hydrochloric acid; purified water - acular eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis. acular eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; benzalkonium chloride; octoxinol 40; sodium hydroxide; water for injections; disodium edetate; hydrochloric acid - ketorolac medicianz eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis.,ketorolac medicianz eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: water for injections; benzalkonium chloride; octoxinol 40; hydrochloric acid; sodium chloride; disodium edetate; sodium hydroxide - ketorolac medsurge eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic,conjunctivitis.,ketorolac medsurge eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - ketorolac trometamol, quantity: 5 mg/ml - ear drops, solution - excipient ingredients: benzalkonium chloride; hydrochloric acid; sodium hydroxide; disodium edetate; octoxinol 40; water for injections; sodium chloride - ketorolac mlabs eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis.,ketorolac mlabs eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - ketorolac trometamol - solution for injection - 30mg/1ml

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 30 mg in 1 ml - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration, and adverse reactions). patients s

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 30 mg in 1 ml - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration, and adverse reactions ). patients should be switched to alter

United States - English - NLM (National Library of Medicine)

readymeds - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 10 mg - carefully consider the potential benefits and risks of ketorolac tromethamine tablets and other treatment options before deciding to use ketorolac tromethamine tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. ketorolac tromethamine tablets are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with ketorolac tromethamine-iv or im and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine-iv/im and ketorolac tromethamine tablets is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration and adverse reactions). patients should be switched to alternative a